Technical Analysis for PAB - Patrys Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Uptrend | Bullish | 12.50% | |
| Narrow Range Bar | Range Contraction | 12.50% | |
| Wide Bands | Range Expansion | 12.50% | |
| Narrow Range Bar | Range Contraction | 12.50% | |
| Wide Bands | Range Expansion | 12.50% | |
| Stochastic Sell Signal | Bearish | 12.50% | |
| Narrow Range Bar | Range Contraction | 12.50% | |
| Earnings Movers | Other | 12.50% | |
| Wide Bands | Range Expansion | 12.50% | |
| Overbought Stochastic | Strength | 12.50% |
| Alert | Time |
|---|---|
| 3x Volume Pace | 7 days ago |
| 2x Volume Pace | 7 days ago |
| 1.5x Volume Pace | 7 days ago |
| Gap Up Closed | 8 days ago |
| Upper Bollinger Band Resistance | 8 days ago |
Get a Trading Sidekick!
Patrys Limited Description
Patrys Limited is engaged in the commercialization of its technologies to develop natural human antibody-based therapeutic products for the treatment of cancer. The Company is engaged in conducting research and development activities in the biopharmaceutical sector. The Company's products include PAT-SM6, PAT-LM1 and PAT-SC1. PAT-SM6 is a natural human antibody that binds to multiple types of cancer, including solid tumors, such as melanoma, breast, colon and pancreatic, as well as blood-based cancers, such as multiple myeloma. PAT-SM6 has completed its Phase I clinical trials for melanoma and Phase I/IIa clinical trials for multiple myeloma. PAT-LM1 is a natural human antibody that can be used for treatment of multiple types of cancer, with potency against colon, lung, breast, ovary and pancreatic cancers. PAT-LM1 is in pre-clinical stage of its study. It offers 3E10 Deoxymab, a lupus autoantibody. It is toxic to cancer cell that has deficiencies in deoxyribonucleic acid repair.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Pharmaceutical Cancer Clinical Medicine Clinical Trial Biopharmaceutical Cancers Ducting Therapeutic Product Therapeutic Products Tumor Tumors Melanoma Solid Tumors Treatment Of Cancer Multiple Myeloma Pancreatic Cancer Pancreatic Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.011 |
| 52 Week Low | 0.003 |
| Average Volume | 2,344,827 |
| 200-Day Moving Average | 0.007 |
| 50-Day Moving Average | 0.005 |
| 20-Day Moving Average | 0.004 |
| 10-Day Moving Average | 0.004 |
| Average True Range | 0.001 |
| RSI (14) | 50.00 |
| ADX | 26.65 |
| +DI | 35.065 |
| -DI | 11.688 |
| Chandelier Exit (Long, 3 ATRs) | 0.003 |
| Chandelier Exit (Short, 3 ATRs) | 0.005 |
| Upper Bollinger Bands | 0.005 |
| Lower Bollinger Band | 0.003 |
| Percent B (%b) | 0.67 |
| BandWidth | 48.649 |
| MACD Line | -0.001 |
| MACD Signal Line | -0.001 |
| MACD Histogram | 0.0001 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.004 | ||||
| Resistance 3 (R3) | 0.004 | 0.004 | 0.004 | ||
| Resistance 2 (R2) | 0.004 | 0.004 | 0.004 | 0.004 | |
| Resistance 1 (R1) | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Pivot Point | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Support 1 (S1) | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Support 2 (S2) | 0.004 | 0.004 | 0.004 | 0.004 | |
| Support 3 (S3) | 0.004 | 0.004 | 0.004 | ||
| Support 4 (S4) | 0.004 |
